70% Remission for Postpartum Depression? The Psychedelic Breakthrough
April 30, 2026
Postpartum depression treatment advances with psychedelic therapy. Greg Mayes of Reunion Neuroscience discusses luvesilocin drug development. This episode explores how shorter-acting psilocybin analogs offer new hope for mothers. Greg highlights the success of the RECONNECT study and the path to FDA breakthrough designation.
Psychedelic therapy for postpartum depression shows breakthrough results. Reunion Neuroscience CEO Greg Mayes details luvesilocin clinical trials. While many developers focus on treatment-resistant depression, Reunion is carving a path through postpartum depression and adjustment disorder. Greg shares insights from his transition from legal counsel to biotech CEO, emphasizing the operational rigor required to bring these paradigm-shifting molecules to market.
The conversation covers the science of 4-OH-DiPT prodrugs, which provide a therapeutic experience in roughly half the time of traditional psilocybin. Greg explains why targeting niche indications like oncology-related adjustment disorder can lead to blockbuster opportunities. We also dive into the realities of biotech fundraising and why resilience is the most critical asset for any life sciences leader.
What You’ll Learn:
- Why postpartum depression remains a massive unmet medical need in psychiatry.
- The clinical significance of luvesilocin and its 70 percent remission rate.
- How shorter-acting psychedelic experiences improve clinical operations and patient access.
- The strategic reasoning behind choosing adjustment disorder as a lead indication.
- Why the FDA recommended expanding research into ALS, Parkinson’s, and MS.
- The difference between psychedelic therapies and non-hallucinogenic neuroplasticogens.
- Lessons from a 25-year career transitioning from law to biotech operations.
- How to navigate the "numbers game" of raising a $132 million Series A.
About the Guest:
Greg Mayes is the President and CEO of Reunion Neuroscience. With a 25-year career in life sciences, he has served as lead oncology counsel at AstraZeneca and played a key role in the $6.5 billion sale of ImClone Systems to Eli Lilly. A personal experience with his son’s epilepsy diagnosis led him to transition into biotech operations, where he now focuses on delivering paradigm-changing therapies for mental health and neurological disorders.
Episode Resources: